Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting
The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Daniele Mauro¹, Federica Macaluso ², Alessandra Nerviani ³, Marie-Astrid Boutet ³, Aroldo Rizzo ⁴, Riccardo Alessandro ², Giuliana Guggino ², Costantino Pitzalis ³ and Francesco Ciccia ⁵, ¹Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, England, United Kingdom, ²University of Palermo, Italy, Palermo, Italy, ³Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁴Pathology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy., Palermo, Italy, ⁵University of Campania L. Vanvitelli, Naples, Italy
Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…
Abstract Number: 434 • 2019 ACR/ARP Annual Meeting
Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials
Cheng-Chung Wei¹, Theresa Hunter ², Filip Van den Bosch ³, Jessica Walsh ⁴, Uta Kiltz ⁵, Yan Dong ⁶, David Sandoval ⁶, Luis Leon ⁶, Vibeke Strand ⁷ and Xiaoqi Li ², ¹Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ²Eli Lilly and Company, Indianapolis, ³Ghent University Hospital, Ghent, Belgium, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Previous trials have used the Short Form (SF)-36 questionnaire to evaluate the impact of ankylosing spondylitis/radiographic axial spondyloarthritis (AS/r-axSpA) on health-related quality of life…
Abstract Number: 614 • 2019 ACR/ARP Annual Meeting
Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data
Bon San Koo¹, Yu-Cheol Lim ², Min-Young Lee ³, Ja-Young Jeon ⁴, Hyun-Jeong Yoo ⁵, In-Sun Oh ², Ju-Young Shin ² and Tae-Hwan Kim ⁶, ¹Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ²School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea, ³VIAplus, Siheung, Republic of Korea, ⁴Pfizer Inc, Seoul, Republic of Korea, ⁵Pfizer Korea, Seoul, Republic of Korea, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Tapering of tumor necrosis factor (TNF) inhibitors may be considered in patients with ankylosing spondylitis (AS) with low disease activity. However, there is still…
Abstract Number: 1267 • 2019 ACR/ARP Annual Meeting
Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study
Iñigo Gonzalez-Mazon¹, Lara Sanchez-Bilbao ², Javier Rueda-Gotor ³, DAVID MARTINEZ-LOPEZ ⁴, DIANA PRIETO- PENA ¹, Mónica Calderón-Goercke ⁵, Jose Luis Martín-Varillas ², Belén Atienza-Mateo ², Miguel A Gonzalez-Gay ² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Uveitis is one of the most frequent extra articular manifestation of spondyloarthritis (SpA). Biological therapy, especially monoclonal TNF inhibitors, are useful to prevent and…
Abstract Number: 1819 • 2019 ACR/ARP Annual Meeting
The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index
Sarah Sacks¹, Kathryn Rigler ² and Antoni Chan ², ¹Royal Berkshire Hospital, Maidenhead, United Kingdom, ²Royal Berkshire Hospital, Reading, United Kingdom
Background/Purpose: Currently the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Spinal pain are used to assess whether a patient with Axial Spondyloarthritis (AxSpA) requires…
Abstract Number: L13 • 2018 ACR/ARHP Annual Meeting
Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
Xenofon Baraliakos¹, Jürgen Braun², Atul A. Deodhar³, Denis Poddubnyy⁴, Alan J. Kivitz⁵, Hasan Tahir⁶, Filip van Den Bosch⁷, Evie Maria Delicha⁸, Zsolt Talloczy⁹ and Anke Fierlinger⁹, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Oregon Health & Science University, Portland, Portland, OR, ⁴Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, ⁷Rheumatology, Universitair Ziekenhuis, Ghent, Belgium, Gent, Belgium, ⁸Novartis Pharma AG, Basel, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States, East Hanover, NJ
Background/Purpose: Clinical evaluation of efficacy and safety for long-term treatment for ankylosing spondylitis (AS) is important for treatment decision-making. Secukinumab (SEC), a fully human mAb…
Abstract Number: 677 • 2018 ACR/ARHP Annual Meeting
Structural Damage Characteristics of Patients with Ankylosing Spondylitis in China
Weiping Kong¹, Caroline Jefferies², Thomas Learch³, Jinrui Cui⁴, Xiaowei Gan¹, Nan Zhang¹, Yingze Zhang¹, Jianming Wang¹, Qingwen Tao¹, Xiaoping Yan¹, Michael Weisman⁵ and Mariko Ishimori⁶, ¹China-Japan Friendship Hospital, Beijing, China, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Radiology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Harbor UCLA Medical Center, Los Angeles, CA, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Structural damage is a major cause of poor outcomes in patients with ankylosing spondylitis (AS). In China, structural damage characteristics of AS are rarely…
Abstract Number: 1517 • 2018 ACR/ARHP Annual Meeting
Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Arthur Kavanaugh¹, Atul A. Deodhar², Sergio Schwartzman³, Shelly Kafka⁴, Soumya D Chakravarty⁵, Elizabeth C Hsia⁶, Diane D. Harrison⁷, Jocelyn Leu⁷, Yiying Zhou⁷, Kim Hung Lo⁷ and M. Elaine Husni⁸, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Oregon Health & Science U, Portland, OR, ³Weill Cornell Medical College, New York, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁶Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH
Background/Purpose: The GO-FURTHER, GO-VIBRANT, and GO-ALIVE randomized controlled trials evaluated the efficacy and safety of intravenous (IV) golimumab (GLM) in patients (pts) with active rheumatoid…
Abstract Number: 2066 • 2018 ACR/ARHP Annual Meeting
Serum IL-37 Is an Efficient Biomarker of Disease Activity and Treatment Response in Patients with Ankylosing Spondylitis
Ga Young Ahn¹, Su Man Kang², Juyeon Kang¹, Bora Nam¹, Hyuk-Hee Kwon¹, Tae-Hwan Kim³ and Dae-Hyun Yoo¹, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Institute of Rheumatology, Hanyang University, Seoul, Korea, Republic of (South), ³Rheumatology, The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The measurement of disease activity is mainly dependent on the patient-reported outcome measures in ankylosing spondylitis (AS) patients. Current inflammatory biomarkers have insufficient sensitivity…
Abstract Number: 678 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?
Shahla Vahidfar¹, Ismihan Sunar², Sebnem Ataman³, Gürkan Yılmaz⁴, Javid M. AZARABADI⁵ and Ayşe Bölükbaşı¹, ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Department of Physical Medicine and Rehabilitation, Division of Rheumatology,, Ankara University, Faculty of Medicine, Ankara, Turkey, ³Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ⁴Physical Medicine and Rehabilitation, Rheumatology Division, Ankara University Faculty of Medicine, Ankara, Turkey, ⁵ORTHOPEDICS AND TRAUMATOLOGY, Başkent University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Along with emergence of the term of ‘non-radiographic axial SpA’ (nr-AxSpA), studies comparing AS and nr-AxSpA in terms of genetic, epidemiologic, and clinical issues…
Abstract Number: 1594 • 2018 ACR/ARHP Annual Meeting
Liver Enzyme Elevation in Patients with Ankylosing Spondylitis Treated with TNF Inhibitor: A Single-Center Historical Cohort Study
Su Jin Choi, Ji Seon Oh, Seokchan Hong, Yong-Gil Kim, Chang Keun Lee and Bin Yoo, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: TNF inhibitors have been known to cause liver enzyme elevation in rheumatologic disease. However, liver enzyme elevation could be affected easily by other causes…
Abstract Number: 2067 • 2018 ACR/ARHP Annual Meeting
Dysbiosis-Dependent Inflammasomes Activation Drives Innate Immune Responses in Ankylosing Spondylitis Patients
Francesco Ciccia¹, Giuliana Guggino¹, Aroldo Rizzo², Stefania Raimondo³, Simon Milling⁴ and Riccardo Alessandro³, ¹Rheumatology Unit, University of Palermo, Palermo, Italy, ²Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy, ³University of Palermo, Palermo, Italy, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: A growing body of evidences indicate that the aberrant activation of innate immune systems, occurring in genetically predisposed patients, drives inflammatory processes in Ankylosing…
Abstract Number: PP12 • 2018 ACR/ARHP Annual Meeting
Living a Full Life with A.S. Through Adaptations
Gail Wright, Spondylitis Association of America, Buffalo Grove, IL
Background/Diagnosis: After running a half marathon and 2 5’ks, I had unexplained back/ hip pain that wouldn’t resolve. I returned to my PT. After 3…
Abstract Number: 682 • 2018 ACR/ARHP Annual Meeting
Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis
Jean Liew¹, John D. Reveille², Michael Ward³, MinJae Lee⁴, Matthew Brown⁵, Mohammad H. Rahbar⁶, Michael Weisman⁷ and Lianne S. Gensler⁸, ¹Internal Medicine; Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ³National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁴Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, USA, Los Angeles, CA, ⁸University of California San Francisco, San Francisco, CA
Background/Purpose: Cardiovascular morbidity and mortality are increased in Ankylosing Spondylitis (AS). Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first line pharmacological therapy in AS; however, their…
Abstract Number: 1597 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
Jürgen Braun¹, Bjoern Buehring¹, Xenofon Baraliakos¹, Lianne S. Gensler², Brian Porter³, Abhijit Shete⁴, Erhard Quebe-Fehling⁵ and Sibylle Haemmerle⁵, ¹Ruhr-University Bochum, Herne, Germany, ²University of California, San Francisco, CA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Low bone mass is common in ankylosing spondylitis (AS) and patients (pts) with AS have an increased risk of bone fracture.1-3 Treatment of AS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].